Marker Therapeutics (MRKR) Competitors $0.90 +0.04 (+4.30%) Closing price 04:00 PM EasternExtended Trading$0.88 -0.02 (-2.10%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRKR vs. COEP, KALA, MNOV, GNTA, INMB, CUE, IMMX, SLGL, ALGS, and ALXOShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Coeptis Therapeutics (COEP), KALA BIO (KALA), MediciNova (MNOV), Genenta Science (GNTA), INmune Bio (INMB), Cue Biopharma (CUE), Immix Biopharma (IMMX), Sol-Gel Technologies (SLGL), Aligos Therapeutics (ALGS), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Its Competitors Coeptis Therapeutics KALA BIO MediciNova Genenta Science INmune Bio Cue Biopharma Immix Biopharma Sol-Gel Technologies Aligos Therapeutics ALX Oncology Coeptis Therapeutics (NASDAQ:COEP) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk. Which has preferable valuation & earnings, COEP or MRKR? Marker Therapeutics has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.12Marker Therapeutics$6.59M1.76-$10.73M-$1.37-0.65 Is COEP or MRKR more profitable? Coeptis Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -271.12%. Marker Therapeutics' return on equity of -114.59% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -201.73% -108.46% Marker Therapeutics -271.12%-114.59%-90.31% Does the media prefer COEP or MRKR? In the previous week, Coeptis Therapeutics had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Coeptis Therapeutics and 1 mentions for Marker Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.84 beat Marker Therapeutics' score of 0.50 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coeptis Therapeutics Positive Marker Therapeutics Positive Do analysts rate COEP or MRKR? Marker Therapeutics has a consensus target price of $13.17, suggesting a potential upside of 1,368.18%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Which has more risk & volatility, COEP or MRKR? Coeptis Therapeutics has a beta of -0.57, suggesting that its stock price is 157% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Do institutionals & insiders have more ownership in COEP or MRKR? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryMarker Therapeutics beats Coeptis Therapeutics on 12 of the 16 factors compared between the two stocks. Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.61M$2.64B$5.77B$9.93BDividend YieldN/A49.35%6.67%4.52%P/E Ratio-0.6523.0375.6026.68Price / Sales1.76752.40555.18213.69Price / CashN/A169.7737.1158.92Price / Book0.525.5011.446.09Net Income-$10.73M$32.95M$3.28B$266.14M7 Day Performance-3.12%2.69%0.84%0.27%1 Month Performance-28.26%7.87%7.15%4.13%1 Year Performance-71.35%0.79%59.65%23.93% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics4.1812 of 5 stars$0.90+4.3%$13.17+1,368.2%-72.1%$11.61M$6.59M-0.6560Short Interest ↓COEPCoeptis Therapeutics1.476 of 5 stars$13.65+1.4%N/A+203.2%$64.88MN/A-2.352Short Interest ↓Gap UpKALAKALA BIO2.8394 of 5 stars$8.78-4.7%$13.00+48.1%+141.4%$64.66M$3.89M-1.2930Trending NewsAnalyst UpgradeAnalyst RevisionGap DownMNOVMediciNova1.9404 of 5 stars$1.32+0.6%$7.00+430.3%-24.0%$64.37M$1M-5.2810GNTAGenenta Science2.7607 of 5 stars$3.50-0.4%$25.00+615.3%-13.6%$64.20MN/A0.007Gap UpHigh Trading VolumeINMBINmune Bio2.87 of 5 stars$2.24-7.1%$18.40+721.4%-68.8%$64.07M$10K-0.9010CUECue Biopharma1.3329 of 5 stars$0.82-0.9%N/A+18.8%$63.47M$9.29M-1.4660High Trading VolumeIMMXImmix Biopharma3.3932 of 5 stars$2.10-4.1%$7.00+233.3%+8.8%$63.15MN/A-2.739Short Interest ↓SLGLSol-Gel Technologies1.4542 of 5 stars$21.00-7.4%N/A+307.3%$63.15M$11.54M-17.0750News CoverageShort Interest ↓Gap UpALGSAligos Therapeutics4.2859 of 5 stars$10.21+0.1%$50.00+389.7%-8.5%$62.74M$3.94M-0.5290High Trading VolumeALXOALX Oncology4.1729 of 5 stars$1.10-6.0%$3.30+200.0%-47.6%$62.65MN/A-0.5040News CoverageShort Interest ↓Gap Down Related Companies and Tools Related Companies Coeptis Therapeutics Alternatives KALA BIO Alternatives MediciNova Alternatives Genenta Science Alternatives INmune Bio Alternatives Cue Biopharma Alternatives Immix Biopharma Alternatives Sol-Gel Technologies Alternatives Aligos Therapeutics Alternatives ALX Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRKR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRKR Stock Alerts